Skip to main content
Article thumbnail
Location of Repository

The role of protein aggregation in Huntington's disease

By Claire Martina Didszun


Huntington’s disease (HD) is a hereditary progressive neurodegenerative\ud disorder characterised by chorea, general motor impairment, psychiatric\ud disturbances and dementia, leading to death within 10 to 20 years of onset.\ud It is caused by a (CAG)n trinucleotide repeat expansion in the gene IT15\ud that is translated into a prolonged polyglutamine tract in the protein huntingtin.\ud This mutation leads to the self-association of huntingtin to form aggregates in\ud the brains of affected people.\ud Work in Professor Nicotera’s group at the MRC Toxicology Unit identified\ud expression changes in Rab11, a protein involved in endosomal recycling, in a\ud cell culture model of HD. The aim of this thesis was to investigate whether\ud endosomal recycling is affected in this model. Monitoring the trafficking of\ud labelled transferrin by Western blotting and live-cell imaging showed rapid\ud uptake of transferrin into all cells, but a significantly reduced rate of clearance in\ud cells containing huntingtin aggregates, which was associated with the\ud accumulation of transferrin in the endosomal recycling compartment (ERC).\ud This finding demonstrates an aggregate-specific lesion in the exit of cargo from\ud the ERC in the absence of cell death. As endosomal recycling is essential for\ud correct neuronal function, this process provides a mechanism whereby protein\ud inclusions may contribute to the cognitive and motor deficits seen in HD.\ud A second project focused on purification of aggregates to determine if they\ud could sequester material important for cellular function. Many attempts to purify\ud the aggregates in their intact globular form revealed their highly unspecific\ud affinity towards other proteins, which renders purification methods very\ud susceptible to artefacts. The large globular aggregates could, however, be\ud dispersed by SDS-treatment into fibrils of approximately 10 nm diameter, which\ud were subsequently purified and visualised by electron microscopy

Publisher: University of Leicester
Year: 2010
OAI identifier:

Suggested articles


  1. (2005). (CAG)(n)-hairpin DNA binds to Msh2-Msh3 and changes properties of mismatch recognition.
  2. (1998). A cellular model that recapitulates major pathogenic steps of Huntington's disease.
  3. (2008). A function of huntingtin in guanine nucleotide exchange on
  4. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
  5. (1983). A polymorphic DNA marker genetically linked to Huntington's disease.
  6. (1999). A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.
  7. (2009). a). Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease.
  8. (2006). a). Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
  9. (2005). Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
  10. (2001). Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.
  11. (2002). Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy.
  12. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.
  13. (1998). Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
  14. (2003). Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein.
  15. (1998). Aggresomes: a cellular response to misfolded proteins.
  16. (2001). Altered line is associated with degradation of CREB-binding protein.
  17. (2002). Amyloid fibers are water-filled nanotubes.
  18. (1999). An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles.
  19. (1988). Anticipation in Huntington's disease is inherited through the male line but may originate in the female.
  20. (2008). ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.
  21. (2003). Autophagy Regulates the Processing of Amino Terminal Huntingtin Fragments. Hum Mol Genet.
  22. (2006). b). Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
  23. (2009). b). Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity.
  24. (2000). Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease.
  25. (1999). Biochemical analysis of distinct Rab5- and Rab11-positive endosomes along the transferrin pathway.
  26. (2000). Brain-derived neurotrophic factor in Huntington disease.
  27. (1995). CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain.
  28. (2002). Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons.
  29. (2001). Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
  30. (2005). Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity.
  31. (1995). Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form.
  32. (2006). Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers.
  33. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera.
  34. (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
  35. (2001). Chemistry and biology of eukaryotic iron metabolism.
  36. (2005). CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo.
  37. (1863). Chronic hereditary chorea.
  38. (2005). Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
  39. (1997). CREB: a major mediator of neuronal neurotrophin responses.
  40. (2004). Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.
  41. (2006). Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state.
  42. (2004). Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.
  43. (2000). Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.
  44. (2006). Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
  45. (2009). Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
  46. (2008). Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling.
  47. (2001). Early and progressive accumulation of reactive microglia in the Huntington disease brain.
  48. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.
  49. (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse.
  50. (2000). Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
  51. (2006). Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
  52. (2004). Endocytic recycling.
  53. (2009). Endocytic trafficking and recycling maintain a pool of mobile surface AMPA receptors required for synaptic potentiation.
  54. (2006). ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
  55. (2004). Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins.
  56. (1999). Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
  57. (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease.
  58. (1999). Evidence for the GluR6 gene associated with younger onset age of Huntington's disease.
  59. (2002). Export from pericentriolar endocytic recycling compartment to cell surface depends on stable, detyrosinated (glu) microtubules and kinesin.
  60. (1997). Fast transport and retrograde movement of huntingtin and HAP 1 in axons.
  61. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
  62. (1999). Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin.
  63. (2002). Function and regulation of CREB family transcription factors in the nervous system.
  64. (2007). Functional compartmentalization of endosomal trafficking for the synaptic delivery of AMPA receptors during long-term potentiation.
  65. (2001). Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.
  66. (2006). Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease.
  67. (1997). Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.
  68. (2005). Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic
  69. (2008). Glutamate receptor dynamics in dendritic microdomains.
  70. (2000). Glutamine repeats and neurodegeneration.
  71. (1994). Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.
  72. (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
  73. (2000). HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosomerelated functions.
  74. (1995). HEAT repeats in the Huntington's disease protein.
  75. (1997). HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membraneassociated huntingtin in the brain.
  76. (2003). Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
  77. (2008). Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
  78. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
  79. (2003). Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.
  80. (1987). Homozygotes for Huntington's disease.
  81. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules.
  82. (2000). Huntingtin expression stimulates endosomallysosomal activity, endosome tubulation, and autophagy.
  83. (2002). Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
  84. (2006). Huntingtin inhibits caspase-3 activation.
  85. (2005). Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain.
  86. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.
  87. (1995). Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.
  88. (1997). Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.
  89. (2005). Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo.
  90. (2006). Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity.
  91. (2008). Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued.
  92. (2008). Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease.
  93. (2004). Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
  94. (2001). Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing.
  95. (1997). Huntingtinencoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.
  96. (1999). Huntington aggregates may not predict neuronal death in Huntington's disease.
  97. (1998). Huntington disease.
  98. (1993). Huntington's disease gene (IT15) is widely expressed in human and rat tissues.
  99. (1995). Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals.
  100. (2009). Huntington's disease: the case for genetic modifiers.
  101. (1998). Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes.
  102. (1995). Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies.
  103. (1999). Identification of a putative effector protein for rab11 that participates in transferrin recycling.
  104. (2001). Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression.
  105. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation.
  106. (1995). Inactivation of the mouse Huntington's disease gene homolog Hdh.
  107. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue.
  108. (2002). Increased sensitivity to Nmethyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
  109. (2000). Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells.
  110. (2006). Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
  111. (2004). Inhibition of calpain cleavage of Huntingtin reduces toxicity: Accumulation of calpain/caspase fragments in the nucleus.
  112. (2004). Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.
  113. (2008). Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.
  114. (2001). Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
  115. (2007). Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes.
  116. (1998). Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.
  117. Letter on chorea.
  118. (2001). Loss of huntingtinmediated BDNF gene transcription in Huntington's disease.
  119. (2005). Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
  120. (2002). Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
  121. (2006). Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
  122. (2007). Microglial activation in presymptomatic Huntington's disease gene carriers.
  123. (2004). Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases.
  124. (2007). Modulation of nucleosome dynamics in Huntington's disease.
  125. (1993). Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent.
  126. (2000). Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease.
  127. (1988). Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.
  128. (1999). Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice.
  129. (2004). Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.
  130. (2009). Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus.
  131. (2006). Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo.
  132. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
  133. (2001). Mutant protein in Huntington disease is resistant to proteolysis in affected brain.
  134. (2002). Mutation analysis and association studies of the ubiquitin carboxyterminal hydrolase L1 gene in Huntington's disease.
  135. (2001). Myosin vb is associated with plasma membrane recycling systems.
  136. (2008). Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic plasticity.
  137. (1985). Neuropathological classification of Huntington's disease.
  138. (2005). Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
  139. (2005). New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils.
  140. (2005). NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.
  141. (1999). Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.
  142. (1996). of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
  143. On chorea.
  144. (2002). Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease.
  145. (2009). PGC-1alpha as modifier of onset age in Huntington disease.
  146. (1996). Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.
  147. (2009). Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments.
  148. (2008). Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.
  149. (2006). Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes.
  150. (2001). Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
  151. (2002). Polyglutamine protein aggregates are dynamic.
  152. (2008). Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E).
  153. (2004). Protein aggregation and neurodegenerative disease.
  154. (2005). Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.
  155. (1983). Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.
  156. (2009). Rab GTPases as coordinators of vesicle traffic.
  157. (2001). Rab proteins as membrane organizers.
  158. (1996). Rab11 regulates recycling through the pericentriolar recycling endosome.
  159. (2000). Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-golgi network.
  160. Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis.
  161. (2002). Rab11a and myosin Vb regulate recycling of the M4 muscarinic acetylcholine receptor.
  162. (2006). Rabs and their effectors: achieving specificity in membrane traffic.
  163. (2009). Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.
  164. (2002). Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi.
  165. (2007). Recycling endosomes in neuronal membrane traffic.
  166. Recycling endosomes supply AMPA receptors for LTP.
  167. (2006). Regional and cellular gene expression changes in human Huntington's disease brain.
  168. (2006). Regulation of intracellular trafficking of huntingtin-associated protein-1 is critical for TrkA protein levels and neurite outgrowth.
  169. (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.
  170. (2007). Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.
  171. (2002). Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
  172. (2008). Rodent genetic models of Huntington disease.
  173. (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet.
  174. (1999). Self-assembly of polyglutaminecontaining huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.
  175. (2009). Single neuron ubiquitinproteasome dynamics accompanying inclusion body formation in huntington disease.
  176. (2007). Small molecule enhancers of rapamycininduced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages.
  177. (2007). Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
  178. (1994). Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm.
  179. (1995). Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease.
  180. (2004). Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
  181. (2009). Spine microdomains for postsynaptic signaling and plasticity.
  182. (1999). Structural view of the Ran-Importin beta interaction at 2.3 A resolution.
  183. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.
  184. (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.
  185. (2006). The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions.
  186. (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.
  187. (2009). The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease.
  188. (2001). The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.
  189. (2008). The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
  190. (1993). The Huntington's Disease Collaborative Research Group
  191. (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.
  192. (2002). The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.
  193. (1998). The influence of huntingtin protein size on nuclear localization and cellular toxicity.
  194. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.
  195. (2004). The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin.
  196. (2006). Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
  197. (2003). Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
  198. (1994). Transcriptional activation modulated by homopolymeric glutamine and proline stretches.
  199. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
  200. (2001). Trinucleotide expansion in haploid germ cells by gap repair.
  201. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease.
  202. (2007). Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
  203. (1999). Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet.
  204. (2004). Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.
  205. (2007). Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.
  206. (1995). Widespread expression of Huntington's disease gene (IT15) protein product.
  207. (1993). Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues.
  208. (2001). Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
  209. (1998). Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways.
  210. (2006). Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
  211. (2000). Wild-type huntingtin protects from apoptosis upstream of caspase-3.
  212. (2001). Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.